ENTX Stock Summary and Trading Ideas (Entera Bio Ltd. - | NASDAQ:ENTX)

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Entera Bio Ltd. - trades on the NASDAQ stock market under the symbol ENTX.

As of May 15, 2026, ENTX stock price declined to $1.26 with 71,293 million shares trading.

ENTX has a beta of -0.82, meaning it tends to be less sensitive to market movements. ENTX has a correlation of 0.01 to the broad based SPY ETF.

ENTX has a market cap of $62.02 million. This is considered a Micro Cap stock.

In the last 3 years, ENTX traded as high as $3.35 and as low as $.52.

ENTX has underperformed the market in the last year with a return of -37.2%, while the SPY ETF gained +26.4%. In the last 3 month period, ENTX fell short of the market, returning -16.0%, while SPY returned +8.7%. However, in the most recent 2 weeks ENTX has outperformed the stock market by returning +14.5%, while SPY returned +2.6%.

ENTX support price is $1.24 and resistance is $1.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENTX shares will trade within this expected range on the day.